BusinessActinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical DevelopmentBy Nasdaq OMXApr 18, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform TechnologyBy Nasdaq OMXMar 28, 2018, 12:01 PM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory AffairsBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessActinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXMar 13, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals Announces Commencement of Rights Offering Subscription PeriodBy Nasdaq OMXFeb 22, 2018, 12:31 PM UTC
BusinessActinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AMLBy Nasdaq OMXFeb 12, 2018, 9:15 PM UTC
BusinessActinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of RecordBy Nasdaq OMXFeb 12, 2018, 12:30 PM UTC
BusinessActinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on MyeloablationBy Nasdaq OMXFeb 8, 2018, 1:01 PM UTC
